Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Genmark Diagnostics (GNMK)

Genmark Diagnostics (GNMK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Genmark Diagnostics 5964 LA PLACE COURT CARLSBAD CA 92008 USA

www.genmarkdx.com P: 760-448-4300 F: 760-448-4301

Description:

GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor' XT-8 system is the second generation in GenMark Dx's eSensor' platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California.

Key Statistics

Overview:

Market Capitalization, $K 1,756,987
Shares Outstanding, K 73,086
Annual Sales, $ 171,550 K
Annual Net Income, $ -18,640 K
Last Quarter Sales, $ 50,080 K
Last Quarter Net Income, $ -3,720 K
60-Month Beta 3.05
% of Insider Shareholders 3.25%
% of Institutional Shareholders 99.71%
Float, K 70,711
% Float 96.75%

Growth:

1-Year Return 186.53%
3-Year Return 270.42%
5-Year Return 306.77%
5-Year Revenue Growth 335.30%
5-Year Earnings Growth 72.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 05/03/21
Earnings Per Share ttm -0.21
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 70.59%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

GNMK Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -19.26%
Return-on-Assets % -7.54%
Profit Margin % -10.87%
Debt/Equity 0.76
Price/Sales 10.24
Price/Cash Flow N/A
Price/Book 18.30
Book Value/Share 1.31
Interest Coverage -1.35
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar